Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel and darolutamide pharmacokinetic interaction study in metastatic castration-resistant prostate cancer
NL-OMON50053Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel and darolutamide in prostate cancer (PCa), sponsored by Erasmus MC. Primary endpoint: Cabazitaxel AUC. Started Sep 2020; status: active, not recruiting.
02
Drugs
cabazitaxeldarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON50053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50053.